Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

XEN 2174

Drug Profile

XEN 2174

Alternative Names: XEN-2174

Latest Information Update: 08 Sep 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Xenome
  • Class Analgesics; Peptides
  • Mechanism of Action Adrenergic uptake inhibitors; Catecholamine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer pain; Postoperative pain

Most Recent Events

  • 04 Sep 2012 XEN 2174 is still in phase I/II development for Cancer pain
  • 04 Sep 2012 Discontinued - Phase-I for Postoperative pain (in volunteers) in Australia (IV)
  • 01 Aug 2012 Xenome completes a phase II trial in Postoperative pain in Bulgaria (EudraCT2010-019109-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top